1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Beryl Drugs Limited

Beryl Drugs Limited

BBSE:BERLDRG
24.89
INR
-0.07
(-0.28%)
1.27EPS
17.42P/E
112.54MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
28.77
26.2
25.85
21.3
29.1
24.92
24.78
27.29
28.5
52.62
52.15
41.3
36.84
43.5
Basic EPS, GAAP
0.53
0.17
0.33
-0.88
1.96
1.16
0.09
0.47
-1.3
1.51
1.52
1.12
0.84
1.27
Free Cash Flow per Basic Share
-1.4
0.81
0.73
0.53
-0.35
-5.55
-3.33
-1.41
-1.74
1.63
-1.05
2.19
-0.34
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
12.66
12.81
12.94
11.61
13.15
14.84
15.04
15.63
14.38
15.9
17.57
18.69
19.5
- -
Tangible Book Value per Share
12.66
12.8
12.93
11.59
13.13
14.83
15.02
15.63
14.38
15.9
17.57
18.69
19.49
- -
Basic Weighted Avg Shares
5
5
5
5
5
5
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
146
133
131
108
148
126
126
138
145
267
264
209
187
213
Operating Margin (%)
3.03
2.32
3.63
-4.1
5
5.65
1.96
1.39
-4.53
4.46
4.45
1.17
5.37
5.13
Depreciation Expense
3
5
4
4
3
3
7
13
11
8
12
13
15
14
Net Income, GAAP
3
1
2
-4
10
6
- -
2
-7
8
8
6
4
6
Effective Tax Rate (%)
37.8
37.26
32.18
- -
22.03
25.81
69.64
31.15
- -
22.14
23.88
33.57
27.76
20.76
Profit Margin (%)
1.83
0.64
1.27
-4.14
6.73
4.67
0.38
1.73
-4.56
2.87
2.91
2.71
2.27
2.93
Working Capital
17
22
28
26
31
-1
9
19
20
40
45
47
23
- -
LT Debt
- -
- -
- -
1
1
13
23
20
17
27
25
18
- -
- -
Total Equity
64
65
66
59
67
75
76
79
73
81
89
95
99
- -
Return on Invested Capital (%)
3.65
2.13
3.67
- -
11.66
5.42
0.63
0.93
- -
7.45
6.44
-0.09
4.46
- -
Return on Capital (%)
5.05
2.62
3.63
- -
13.82
7.3
1.17
4.12
- -
8.66
8.32
6.62
5.1
- -
Return on Common Equity (%)
4.26
1.31
2.55
-7.19
15.82
8.32
0.63
3.08
-8.66
9.97
9.05
6.17
4.39
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
24
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
119
98
113

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
68
- -
Cash, Cash Equivalents & STI
- -
3
- -
Accounts Receivable, Net
- -
21
- -
Inventories
- -
31
- -
Total Current Liabilities
- -
45
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
24
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.49%
4.75%
4.29%
Free Cash Flow
45.11%
-151.67%
-115.76%
Net Income, GAAP
-106.54%
-128.45%
-25.15%
Sales/Revenue/Turnover
7.08%
11.31%
-10.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
62
56
53
40
209
2026
48
51
38
51
187
2027
73
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.73
0.01
0.1
0.3
1.12
2026
0.04
0.02
-0.33
1.11
0.84
2027
0.44
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sanjay B. Sethi
Full Time Employees
22
Sector
Health technology
Industry
Pharmaceuticals: other
Address
29, Mayank Water Park Road Indore MP India 452016
IPO Date
Jun 16, 1994
Website
beryldrugs.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Beryl Drugs Limited manufactures and markets branded and generic pharmaceutical formulations in India. The company offers bulk drugs; intravenous (I.V.) fluids; small volume injectables in liquid and dry powder forms; eye and ear drops; veterinary products; along with research and development and contract manufacturing services. Beryl Drugs Limited, founded in 1993 and headquartered in Indore, Madhya Pradesh, operates primarily in the domestic, institutional, and export markets. The company maintains manufacturing facilities compliant with international standards and focuses on pharmaceuticals and allied healthcare products. In recent developments, Beryl Drugs Limited held board meetings in 2025 to approve unaudited financial results for quarters ended June 2025, September 2025, and audited results for the year ended March 2025, alongside preparations for its annual general meeting. No major acquisitions, partnerships, funding rounds, or new product launches occur within the last 1-2 years.